Bio-Path Holdings Shares Were On The Rise: What's Going On?
Bio-Path Holdings Shares Were On The Rise: What's Going On?
Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are surging Thursday following the company's announcement of encouraging preclinical results for BP1001-A, a potential treatment for obesity and Type 2 diabetes. Here's what you need to know.
Bio-Path Holdings, Inc.（納斯達克：BPTH）股票在週四大幅上漲，此前公司宣佈了BP1001-A的令人鼓舞的前臨床結果，這是一種潛在的肥胖和2型糖尿病治療方法。以下是你需要了解的內容。
What To Know: The preclinical studies demonstrated that BP1001-A enhances insulin sensitivity by downregulating the growth factor receptor-bound protein 2. These findings suggest BP1001-A could improve insulin-induced metabolic processes and offer a new therapeutic option for obesity-related metabolic conditions.
需要知道的：前臨床研究表明，BP1001-A通過下調生長因子受體結合蛋白2來增強胰島素敏感性。這些發現表明，BP1001-A可能改善胰島素誘導的代謝過程，併爲與肥胖相關的代謝疾病提供新的治療選擇。
Following these findings, the company began animal studies to validate the efficacy of BP1001-A. Pending success, the company plans on holding a first-in-human Phase 1 clinical trial in 2025 to assess safety, pharmacokinetics, and dosing.
在這些發現之後，公司開始進行動物研究以驗證BP1001-A的療效。如果成功，公司計劃於2025年進行首次人體的1期臨床試驗，以評估安全性、藥代動力學和給藥。
BPTH Price Action: Bio-Path Holdings shares were up 104.8% at $1.37 at the time of writing, according to Benzinga Pro.
BPTH股價動作：根據Benzinga Pro的數據顯示，Bio-Path Holdings的股票在撰寫時上漲了104.8%，報1.37美元。
- Even in 2023, Charlie Munger Said 'Elon Musk Overestimates Himself' But Credited His Success to One Key Factor
- 即使在2023年，查理·芒格也曾表示'埃隆·馬斯克高估了自己'，但將他的成功歸功於一個關鍵因素。
Image Via Shutterstock.
圖片來自Shutterstock。
譯文內容由第三人軟體翻譯。
